Explore Annogen’s News
Annogen announces successful identification of cell-specific promoters for Orchard Therapeutics’ preclinical gene therapy programs
Annogen today announced a research collaboration with Orchard Therapeutics, a global gene therapy leader, for the identification of immune cell-specific human promoters for use in certain pre-clinical hematopoietic stem cell (HSC) gene therapy programs.
Ascend Advanced Therapies and Annogen Collaborate to Improve AAV Production
Ascend Advanced Therapies and Annogen will combine their expertise in AAV biology, vector manufacturing and genetic engineering to improve the quality of recombinant AAV particles used in gene therapy applications.
Corteva Annogen collaborating on functional annotation to accelerate crop improvement
New collaboration in crop engineering Collaborating on functional annotation to accelerate crop improvement Corteva Agriscience™ and Annogen B.V. are working together to functionally annotate thousands of expression elements in maize. Leveraging Annogen's innovative...
Annogen invited to speak at CropIB 2025
We’re thrilled to share that our Founder & CEO, Joris van Arensbergen, has been invited to speak at the prestigious Crop Innovation and Business (CIB) Conference in Cologne, taking place from 30 March – 1 April 2025. Joris will be delivering a talk on Large-scale...
UCSF, Annogen Announce Collaboration to Identify Superior Treg-Specific Promoters
UCSF, Annogen Announce Collaboration to Identify Superior Treg-Specific Promoters Annogen, a leader in gene expression engineering, and the prestigious labs of Qizhi Tang and Brian Shy at University of California, San Francisco (UCSF) today announced a collaboration...
Annogen to perform functional genome annotations for KWS to accelerate crop improvement
Einbeck, Germany; Amsterdam, The Netherlands December 5, 2024 KWS SAAT SE & Co. KGaA and Annogen B.V. today announced a partnership in which Annogen will use its FACE™ platform to functionally annotate non-coding variants that are of interest to KWS. FACE™ is an...
Novel Genetic Switches Make Gene Therapies Safer and More Effective -Financieel Dagblad Interview (Nov 2024)
Article as featured in the Financieel Dagblad (Financial Times), 29 November 2024 (link)
Annogen – KeyGene collaboration demonstrates efficacy of the SuRE™ platform to identify gain-of-function in new variants of crops
KeyGene collaboration demonstrates efficacy of the SuRE™ platform to identify gain-of-function in new variants of crops.
Annogen Announces Research Collaboration with Orchard Therapeutics for the Development of CNS-cell Specific Promoters
Annogen today announced a research collaboration with Orchard Therapeutics, a global gene therapy leader, for the identification of immune cell-specific human promoters for use in certain pre-clinical hematopoietic stem cell (HSC) gene therapy programs.
